A5044773708- Breast Cancer Treatment Studies
- Cancer Treatment and Pharmacology
- BRCA gene mutations in cancer
- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Cancer-related Molecular Pathways
- Advances in Oncology and Radiotherapy
- Cancer therapeutics and mechanisms
- Breast Implant and Reconstruction
- Cancer Cells and Metastasis
- Economic and Financial Impacts of Cancer
- Genetic factors in colorectal cancer
- Lung Cancer Treatments and Mutations
- DNA Repair Mechanisms
- Neutropenia and Cancer Infections
- Health Systems, Economic Evaluations, Quality of Life
- Cancer survivorship and care
- Breast Lesions and Carcinomas
- PARP inhibition in cancer therapy
- Brain Metastases and Treatment
- Genomics and Chromatin Dynamics
- Multiple Myeloma Research and Treatments
- Cancer Research and Treatments
Rutgers, The State University of New Jersey
2014-2024
Rutgers Cancer Institute of New Jersey
2014-2024
Cancer Institute (WIA)
2020
University of Florida
2020
Columbus Oncology and Hematology Associates
2020
Heartland Cancer Research
2015-2018
CancerCare
2018
Huntsman Cancer Institute
2017
Memorial Sloan Kettering Cancer Center
2017
Dana-Farber Cancer Institute
1994-2015
The recurrence score based on the 21-gene breast cancer assay predicts chemotherapy benefit if it is high and a low risk of in absence low; however, there uncertainty about for most patients, who have midrange score.We performed prospective trial involving 10,273 women with hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, axillary node-negative cancer. Of 9719 eligible patients follow-up information, 6711 (69%) had 11 to 25 were randomly assigned receive...
Prior studies with the use of a prospective-retrospective design including archival tumor samples have shown that gene-expression assays provide clinically useful prognostic information. However, prospectively conducted study in uniformly treated population provides highest level evidence supporting clinical validity and usefulness biomarker.We performed prospective trial involving women hormone-receptor-positive, human epidermal growth factor receptor type 2 (HER2)-negative, axillary...
To determine the prognostic significance of triple negative breast cancers with respect to locoregional relapse and distant metastasis in conservatively managed cancer patients.A database conservative (conservative surgery followed by radiation) patients, whom all three markers (estrogen receptor, progesterone HER2/neu) were available, was reviewed. Patients classified as if they tested for markers. Of 482 patients 117 negative.As September 2005, a median follow-up time 7.9 years, study,...
BackgroundStandard first-line treatment of metastatic triple-negative breast cancer (mTNBC) is chemotherapy. However, outcomes are poor, and new options needed. In cohort B the phase II KEYNOTE-086 study, we evaluated pembrolizumab as therapy for patients with PD-L1-positive mTNBC.Patients methodsEligible had centrally confirmed mTNBC, no prior systemic anticancer disease, measurable disease at baseline per RECIST v1.1 by central review, radiographic evidence nervous system metastases, a...
The use of adjuvant chemotherapy in patients with breast cancer may be guided by clinicopathological factors and a score based on 21-gene assay to determine the risk recurrence. Whether level clinical recurrence adds prognostic information is not known.
Purpose We compared nab-paclitaxel or ixabepilone once per week to paclitaxel with bevacizumab as first-line therapy for patients advanced breast cancer (BC) evaluate progression-free survival (PFS) versus paclitaxel. Patients and Methods Eligible were age ≥ 18 years chemotherapy-naive BC. randomly assigned 90 mg/m 2 (arm A), 150 B), 16 C), 3 of 4 weeks. Planned enrollment was 900 patients, which would give 88% power detect a hazard ratio 0.73. Results In all, 799 enrolled, 783 received...
Abstract The importance of the p53 stress response pathway in suppression tumor formation is well documented. In a previous report, single nucleotide polymorphism (SNP309 T/G) was found promoter MDM2 gene resulting higher levels RNA and protein and, consequently, attenuation both vitro vivo. As SNP309 locus region promoter, which regulated by hormonal signaling pathways, G-allele increases affinity well-described cotranscriptional activator nuclear hormone receptors (i.e., Sp1), hypothesis...
A high 21-gene recurrence score (RS) by breast cancer assay is prognostic for distant of early after local therapy and endocrine alone, chemotherapy benefit.To describe clinical outcomes women with a RS who received adjuvant plus in the TAILORx trial, population expected to have rate alone.In this secondary analysis data from multicenter randomized 1389 hormone receptor-positive, ERBB2-negative, axillary node-negative cancer, 26 100 were prospectively assigned receive addition therapy. The...
1008 Background: In KEYNOTE-012, pembro showed durable activity and manageable safety in patients (pts) with PD-L1+ mTNBC. Cohort A of KEYNOTE-086 (NCT02447003) examined the efficacy/safety previously treated mTNBC, regardless PD-L1 expression. Methods: Pts centrally confirmed ≥1 prior chemotherapy for metastatic disease, ECOG PS 0-1 had 200 mg Q3W up to 24 mo; imaging q 9 wk first 12 mo, then wk. Clinically stable pts PD could remain on until next assessment. Primary endpoints: ORR (RECIST...
Platinum compounds have activity in triple-negative breast cancer (TNBC) germline BRCA mutation carriers (BRCA carriers). Limited data exist for estrogen receptor (ER)-positive (+) among carriers. INFORM is a randomized, multicenter, phase II trial comparing pathologic complete response (pCR) rates (ypT0/is, N0) after neoadjuvant single-agent cisplatin (CDDP) versus doxorubicin-cyclophosphamide (AC) with stage I-III human epidermal growth factor 2 (HER2)-negative cancer. Secondary objectives...
Purpose Conventionally fractionated postmastectomy radiation therapy (PMRT) takes approximately 5 to 6 weeks. Data supporting hypofractionated PMRT is limited. We prospectively evaluated a short course of PMRT, in which was completed 15 treatment days. Patients and Methods delivered at dose 36.63 Gy 11 fractions 3.33 over days the chest wall draining regional lymph nodes, followed by an optional mastectomy scar boost four Gy. Our primary end point freedom from any grade 3 or higher...
Black race is associated with worse outcomes in early breast cancer. We evaluated clinicopathologic characteristics, the 21-gene recurrence score (RS), treatment delivered, and clinical by ethnicity among women who participated Trial Assigning Individualized Options for Treatment.The association between (White, Black, Asian, other or unknown) (Hispanic vs non-Hispanic) was examined using proportional hazards models. All P values are 2-sided.Of 9719 eligible hormone receptor-positive,...
PURPOSE In the two-cohort phase II KEYNOTE-086 study (ClinicalTrials.gov identifier: NCT02447003 ), first-line and second-line or later pembrolizumab monotherapy demonstrated antitumor activity in metastatic triple-negative breast cancer (mTNBC; N = 254). This exploratory analysis evaluates association between prespecified molecular biomarkers clinical outcomes. METHODS Cohort A enrolled patients with disease progression after one more systemic therapies for irrespective of PD-L1 status; B...
1088 Background: Standard first-line treatment for mTNBC is chemotherapy. However, outcomes are poor, and new options needed. Cohort B of KEYNOTE-086 (NCT02447003) assessed the safety antitumor activity pembrolizumab as therapy patients (pts) with PD-L1–positive mTNBC. Methods: Men women centrally confirmed mTNBC, no prior systemic anticancer metastatic disease, ECOG PS 0-1, a tumor PD-L1 combined positive score (CPS) ≥1% received 200 mg Q3W 24 mo or until disease progression, intolerable...
Performing DNA genetic testing (DGT) for hereditary cancer genes is now a well-accepted clinical practice; however, the interpretation of variation remains challenge laboratories and clinicians. Adding RNA (RGT) enhances DGT by clarifying actionability gene variants, thus improving clinicians' ability to accurately apply strategies risk reduction treatment.To evaluate whether RGT associated with improvement in diagnostic outcome delivery personalized management patients...
Human U-937 myeloid leukemia cells were selected for resistance to increasing concentrations of the camptothecin derivative, 9-nitro-20(S)camptothecin (9-NC). The isolated single cell clone, designated U-937/CR, was approximately 20-fold resistant 9-NC. Analysis topoisomerase I (topo I) gene expression in U-937/CR demonstrated similar mRNA levels as compared with cells. Immunoblotting an anti-topo serum revealed reactive proteins at 100, 75, and 67 kDa which expressed same level parental...
1004 Background: HER3-DXd is an antibody drug conjugate (ADC) comprised of a fully human anti-HER3 IgG1 monoclonal (patritumab), attached to topoisomerase 1 inhibitor via tetrapeptide-based cleavable linker that has shown promising efficacy in pts with HER3-expressing MBC (Krop, 2022). This 3-part Phase 2 study examines across subsets and defines the pt population likely derive greater benefit (NCT04699630). Methods: Part A reported here (Data cutoff 6Sep2022). Pts had HER2 negative...
The common sense model posits that individuals' understanding of illness is based upon somatic symptoms and life experiences thus may differ significantly from the biomedical view illness. current study used to understand cancer risk perceptions in 99 individuals testing for BRCA1/2 mutations. Specifically, we examined change post-counseling post-result (1) absolute (risk developing one's lifetime) (2) comparative relative general population). Results indicated showed a trend such those with...
Cancer cells can have different patterns of exon usage individual genes when compared to normal tissue, suggesting that alternative splicing may play a role in shaping the tumor phenotype. The discovery and identification gene variants has increased dramatically with introduction RNA-sequencing technology, which enables whole transcriptome analysis known, as well novel isoforms. Here we report transcriptional events among subtypes invasive ductal carcinoma Genome Atlas (TCGA) Breast Invasive...